BK1254 Nonprofit Pharmaceutical Companies
- 462.076
- +13.846+3.09%
開拓藥業-B：年報 2023
Cornerstone Pharmaceutical-B (02616.HK): CEO and Executive Director Yang Jianxin purchased 3.345 million additional shares of the company, with a total purchase of 7,529,500 shares
Gelonghui, April 29 | Cornerstone Pharmaceutical-B (02616.HK) announced that the company was informed by Yang Jianxin, CEO, R&D President and Executive Director, that it purchased a total of 3.345 million shares on the open market with its own capital about six months before the announcement date. Since Yang Jianxin became CEO in August 2022, he has purchased a total of 7,529,500 shares. The purchase price range is HKD0.82 to HKD4.60. After the share purchase, Yang Jianxin held a total of about 4.97% of the company's total issued share capital at the date of the announcement.
聖諾醫藥-B：2023年度報告
Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points
Keymed Biosciences (HKG:2162) said their Class 1 innovative drug CM310 for treating seasonal allergic rhinitis achieved its primary endpoints in a Phase III clinical study, according to a Sunday filin
April 26 Repurchase Collection | Hang Seng Bank, Swire Group A and others bought back one after another. Of these, Hang Seng Bank spent HK$61.74,141 million
According to HKEx's April 29 disclosure documents, $Hang Seng Bank (00011.HK) $ and $Swire Group A (00019.HK) $ repurchased shares. ① $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 26, involving an amount of HK$6,1714,400. The repurchase price per share ranged from HK$103.3 to HK$102.2. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) was 6.314 million shares, accounting for 0.33% of the number of shares issued when the ordinary resolution was passed. ② $too
Keji Pharmaceutical-B (02171.HK): Submission of a rectification report on FDA findings
Gelonghui, April 29 | Keji Pharmaceutical-B (02171.HK) issued an announcement. The rectification report on the Corrective and Preventive Measures (CAPAs) plan has been submitted to the US Food and Drug Administration (FDA). This submission relates to findings in Form 483 issued by the FDA after an inspection of the clinical production site in Tulham, North Carolina in December 2023. The relevant work is progressing smoothly according to the schedule previously submitted. The company promises to work closely with the FDA to prioritize quality and ensure the production of clinical trial products.
Conoa-B (02162): Phase III clinical trial of spoxibimab injection to treat seasonal allergic rhinitis reached the main end
Conoa-B (02162) issued an announcement. The company is pleased to announce that its Class 1 new drug, CM310, recombinant humanized monogram...
On April 26, Heyu-B (02256) spent about HK$472,400 to buy back 149,000 shares
Goodwill B (02256) announced that on April 26, 2024, it cost approximately HK$472,400 to buy back 14.9...
兆科眼科-B：2023 年報
Biocytogen Pharmaceuticals' Loss Narrows in 2023
Biocytogen Pharmaceuticals (Beijing) (HKG:2315) cut its losses to roughly 383 million yuan in 2023 from nearly 602.2 million yuan in the preceding year, according to a Thursday filing with the Hong Ko
Chuangsheng Group-B (06628) spent HK$96,300 to buy back 54,000 shares on April 26
According to the Zhitong Finance App, Chuangsheng Group-B (06628) announced that on April 26, 2024, the company spent HK$96,300 to repurchase 54,000 shares, with a repurchase price of HK$1.71-1.7668 per share.
Zhitong Hong Kong Stock Short Position Statement Statistics|April 26
Zhitong Hong Kong Stock Short Position Statement | April 26
東曜藥業-B：2023年年報
歌禮製藥-B：二零二三年年報
健世科技-B：2023年報
心通醫療-B：2023年度報告
堃博醫療-B：年報2023
中國抗體-B：年度報告2023
Hualing Pharmaceutical's second-generation GKA launches phase 1 clinical trial in the US and completes the enrollment of the first patient
Glonghui, April 26 | Hualing Pharmaceutical (2552.HK) announced that the first phase clinical trial of a second-generation glucokinase activator (second-generation GKA) has officially started in the US, and the first case was enrolled on April 25, local time in the US. The trial was a randomized, double-blind, placebo-controlled, single-dose escalation pharmacokinetics and pharmacodynamics study in 40 US patients with type 2 diabetes (T2D). The second-generation GKA is a new molecular entity with optimized physico-chemical properties. Using Hualing Pharmaceutical's proprietary formulation technology, it is designed for oral administration once a day. Second generation GKA
Kaituo Pharmaceutical-B (09939.HK): Restitution of land use rights located in Pinghu City, Zhejiang Province, China
Kaituo Pharmaceutical-B (09939.HK) announced that on April 25, 2024, the seller Kaituo Pharmaceutical (Zhejiang) Co., Ltd. (a wholly-owned subsidiary between the companies) signed an agreement with the buyer Zhejiang Dushan Port Economic Development Zone Management Committee. According to the agreement, the seller agreed to return the land use rights located in Pinghu City, Zhejiang Province, China, at a cost of approximately RMB 26.07 million.